Memantine - Cerecor

Drug Profile

Memantine - Cerecor

Alternative Names: FP-01 - Cerecor; FP01 lozenges; memantine lozenges

Latest Information Update: 04 Jul 2016

Price : $50

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer Cerecor
  • Class Amines; Analgesics; Antidementias; Antiparkinsonians; Antispastics; Antitussives; Organic bridged compounds; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cough

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 16 Sep 2015 No recent reports on development identified - Phase-II for Cough in USA, Chile and Peru (PO)
  • 12 Sep 2013 Cerecor completes a phase IIb trial in Cough in USA (NCT01703923)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top